TFF Pharmaceuticals shares fell by -1.35% during the day's afternoon session, and are now trading at a price of $0.72. Is it time to buy the dip? To better answer that question, it's essential to check if the market is valuing the company's shares fairly in terms of its earnings and equity levels.
TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company, focuses on developing and marketing pharmaceutical products based on its proprietary Thin Film Freezing, or TFF, technology platform in the United States and Australia. The company belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 24.45 and an average price to book (P/B) ratio of 4.16. In contrast, TFF Pharmaceuticals has a trailing 12 month P/E ratio of -0.61 and a P/B ratio of 1.515.
TFF Pharmaceuticals has moved -88.48% over the last year compared to -7.46% for the S&P 500 — a difference of -81.02%. TFF Pharmaceuticals has a 52 week high of $7.7 and a 52 week low of $0.62.